Eli Lilly Announces Acquisitions of Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics

Why It Matters

The surge underscores the growing demand for GLP‑1 therapies and positions Lilly to capture a broader obesity and diabetes market with an oral option, while the raised guidance and strategic acquisitions signal sustained growth potential for investors.

Key Takeaways

• Q1 revenue rose 56% to $19.8 billion, driven by volume growth
• EPS surged 170% to $8.26 reported, $8.55 non‑GAAP
• FDA approved Foundayo, first oral GLP‑1 pill usable anytime
• Full‑year revenue guidance lifted to $82‑$85 billion
• Acquisitions of Orna, Centessa, Kelonia, Ajax to broaden pipeline

Pulse Analysis

Eli Lilly’s Q1 2026 earnings illustrate how the company’s GLP‑1 franchise is reshaping its revenue profile. S. 7 billion. S. volume and a 95% surge abroad, driven primarily by Mounjaro and Zepbound.

Although realized prices fell 7% in the United States and 25% internationally—partly due to pricing pressures in China—the volume‑led growth more than offset the margin erosion, delivering a 170% EPS jump. The FDA’s approval of Foundayo (orforglipron) marks a pivotal moment for the GLP‑1 market. As the first oral GLP‑1 agent that can be taken anytime without food or water constraints, it promises to broaden patient adherence and capture individuals hesitant about injectable therapies. Early data show efficacy in both obesity and type‑2 diabetes, positioning Foundayo alongside injectable competitors such as Mounjaro and Zepbound while opening a new revenue stream.

Analysts expect the oral formulation to accelerate market penetration, especially in primary‑care settings where convenience drives prescribing decisions. Looking ahead, Lilly’s decision to raise its full‑year revenue target to $82‑$85 billion reflects confidence in sustained GLP‑1 demand and the upside from Foundayo. The company also bolstered its long‑term pipeline through acquisitions of Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics and Ajax Therapeutics, adding assets in oncology, immunology and rare diseases. These deals, combined with ongoing Phase 3 successes for candidates like retatrutide, suggest a diversified growth trajectory beyond the obesity‑diabetes niche. For investors, the blend of near‑term sales momentum and strategic expansion underscores a robust outlook for Lilly’s earnings.

Deal Summary

Eli Lilly disclosed that it has signed agreements to acquire four biotech companies—Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics—as part of its Q1 2026 business development activity. The acquisitions aim to broaden Lilly's pipeline in obesity, diabetes, and oncology. Deal terms were not disclosed.